Psilocybin to Treat Depression in Spinal Cord Injury
NCT07251491
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg). The main question the study aims to answer is: does psilocybin increase the number and severity of adverse (bad) events reported by people with SCI? These may include pain, muscle spasms, symptoms of depression, and symptoms of low or high blood pressure.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Spinal Cord Injury
- Depression - Major Depressive Disorder
- Veteran
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- James J. Peters Veterans Affairs Medical Center
- Last updated on ClinicalTrials.gov
- August 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- James J. Peters Department of Veterans Affairs Medical Center · The Bronx, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.